Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.encep.2017.06.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chronic Tic Disorders in Youth: Clinical Phenotypes and Response to Pharmacological Treatment with Aripiprazole.
Children (Basel)
November 2024
Developmental Psychiatry and Psycopharmacology Unit, IRCCS Stella Maris Foundation, 311 viale del Tirreno, 56018 Pisa, Italy.
Background/objectives: Tic disorders are neurodevelopmental conditions often associated with comorbidities like attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Our aims were: (a) in a sample of youth with tic disorders to explore the clinical and psychopathological characteristics of different phenotypes based on the presence of comorbid ADHD and/or ASD and gender; (b) in a subgroup of patients treated with Aripiprazole, to evaluate symptoms variation over time and to identify potential predictors of response.
Methods: A total of 95 subjects with tic disorders (age range 6 to 17.
Therapeutic Approach to Primary Tic Disorders and Associated Psychiatric Comorbidities.
Brain Sci
December 2024
Movement Disorder Unit, Neurology Department, Hospital de Sant Pau, 08041 Barcelona, Spain.
Background/objectives: The treatment of tics and psychiatric comorbidities is crucial when they affect the patient's well-being and relationships. However, the optimal pharmacological treatment (PT) tailored to each patient's phenotype remains unclear. The primary objective of this study is to describe the clinical characteristics and treatment received for tics and psychiatric comorbidities in our cohort of children and adult patients with tic disorders.
View Article and Find Full Text PDFSafety and Efficacy of Ecopipam in Patients with Tourette Syndrome: A Systematic Review and Meta-analysis.
CNS Drugs
February 2025
Pediatric Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, 249203, India.
Background And Objectives: Ecopipam is a selective antagonist of the dopamine D1 receptor, and its efficacy and safety have recently been explored in several clinical trials involving patients with Tourette syndrome (TS). The objectives of this systematic review were to determine the pooled estimate for efficacy [in terms of reduction in tic Yale Global Tic Severity Scale (YGTSS) scores] and safety of oral ecopipam in subjects with TS.
Methods: All clinical trials that explored the efficacy and/or safety of ecopipam in patients with TS were included to determine the pooled estimate for change in YGTSS, Clinical Global Impression (CGI)-TS, and the severity of comorbid attention-deficit hyperactive disorder (ADHD), obsessive compulsion disorder (OCD), and depressive symptoms, as well as the nature and frequency of adverse effects.
[Kieron O'Connor's scientific contribution to the characterization and treatment of Tourette's syndrome and obsessive-compulsive disorders].
Sante Ment Que
December 2024
Université du Québec à Montréal, Québec, Canada; Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal, Québec, Canada.
Background Researcher and psychologist Kieron Philip O'Connor (1950-2019) pioneered the cognitive and behavioural approach at the Institut universitaire en santé mentale de Montréal (IUSMM). It was there that he began a career as a clinical researcher studying Tourette's syndrome (TS) and obsessive-compulsive and related disorder (OCD). At the time, apart from some behavioural approaches, little cognitive intervention was available to treat chronic tics and obsessive-compulsive disorder.
View Article and Find Full Text PDFConvergent molecular signatures across eating disorders and obsessive-compulsive disorder in the human brain.
medRxiv
November 2024
Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Eating disorders (ED) and obsessive-compulsive disorder (OCD) exhibit significant clinical and genetic overlap, yet their shared molecular mechanisms remain unclear. We conducted a transcriptomic investigation of the dorsolateral prefrontal cortex (DLPFC) and caudate from 86 controls, 57 ED, and 27 OCD cases. ED was associated with robust differentially expressed genes (DEGs): 102 DEGs the DLPFC and 222 in the caudate (FDR < 1%) and replicated in an independent cohort.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!